Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Bussink

Showing results (131-140 of 220) with videos related to

Pageof 22
Sort By:
International Journal of Cancer|October 20, 2010
Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma modelBianca A W Hoeben, Janneke D M Molkenboer-Kuenen, Wim J G Oyen, et al.
BMC Cancer|April 15, 2014
Effect of hypoxia on the expression of αB-crystallin in head and neck squamous cell carcinomaChantal van de Schootbrugge, Elisabeth M J Schults, Johan Bussink, et al.
International Journal of Radiation Oncology, Biology, Physics|May 26, 2005
Hypoxic cell turnover in different solid tumor linesAnna S E Ljungkvist, Johan Bussink, Johannes H A M Kaanders, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 17, 2009
Innovations in radiotherapy planning of head and neck cancers: role of PETEsther G C Troost, Dominic A X Schinagl, Johan Bussink, et al.
Contrast Media & Molecular Imaging|August 6, 2015
PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenograftsLaura K van Dijk, Cheng-Bin Yim, Gerben M Franssen, et al.
International Journal of Radiation Oncology, Biology, Physics|March 17, 2012
Expression of EGFR under tumor hypoxia: identification of a subpopulation of tumor cells responsible for aggressiveness and treatment resistanceIlse J Hoogsteen, Henri A M Marres, Franciscus J A van den Hoogen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2013
PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROSKasper M Rouschop, Ludwig J Dubois, Tom G Keulers, et al.
Acta Oncologica (Stockholm, Sweden)|August 26, 2017
The potential of hyperpolarized <sup>13</sup>C magnetic resonance spectroscopy to monitor the effect of combretastatin based vascular disrupting agentsAne B Iversen, Morten Busk, Lotte B Bertelsen, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Inclusion of Incidental Radiation Dose to the Cardiac Atria and Ventricles Does Not Improve the Prediction of Radiation Pneumonitis in Advanced-Stage Non-Small Cell Lung Cancer Patients Treated With Intensity Modulated Radiation TherapyRobin Wijsman, Frank J W M Dankers, Esther G C Troost, et al.
Plos One|March 2, 2018
18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated studySara Carvalho, Ralph T H Leijenaar, Esther G C Troost, et al.
Pageof 22

Showing results (131-140 of 220) with videos related to

Sort By:
Pageof 22
International Journal of Cancer|October 20, 2010
Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma modelBianca A W Hoeben, Janneke D M Molkenboer-Kuenen, Wim J G Oyen, et al.
BMC Cancer|April 15, 2014
Effect of hypoxia on the expression of αB-crystallin in head and neck squamous cell carcinomaChantal van de Schootbrugge, Elisabeth M J Schults, Johan Bussink, et al.
International Journal of Radiation Oncology, Biology, Physics|May 26, 2005
Hypoxic cell turnover in different solid tumor linesAnna S E Ljungkvist, Johan Bussink, Johannes H A M Kaanders, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 17, 2009
Innovations in radiotherapy planning of head and neck cancers: role of PETEsther G C Troost, Dominic A X Schinagl, Johan Bussink, et al.
Contrast Media & Molecular Imaging|August 6, 2015
PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenograftsLaura K van Dijk, Cheng-Bin Yim, Gerben M Franssen, et al.
International Journal of Radiation Oncology, Biology, Physics|March 17, 2012
Expression of EGFR under tumor hypoxia: identification of a subpopulation of tumor cells responsible for aggressiveness and treatment resistanceIlse J Hoogsteen, Henri A M Marres, Franciscus J A van den Hoogen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2013
PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROSKasper M Rouschop, Ludwig J Dubois, Tom G Keulers, et al.
Acta Oncologica (Stockholm, Sweden)|August 26, 2017
The potential of hyperpolarized <sup>13</sup>C magnetic resonance spectroscopy to monitor the effect of combretastatin based vascular disrupting agentsAne B Iversen, Morten Busk, Lotte B Bertelsen, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Inclusion of Incidental Radiation Dose to the Cardiac Atria and Ventricles Does Not Improve the Prediction of Radiation Pneumonitis in Advanced-Stage Non-Small Cell Lung Cancer Patients Treated With Intensity Modulated Radiation TherapyRobin Wijsman, Frank J W M Dankers, Esther G C Troost, et al.
Plos One|March 2, 2018
18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated studySara Carvalho, Ralph T H Leijenaar, Esther G C Troost, et al.
Pageof 22